MX2024002335A - Combinacion de analogos de relaxina y vasopresina para el tratamiento de trastornos y afecciones renales. - Google Patents

Combinacion de analogos de relaxina y vasopresina para el tratamiento de trastornos y afecciones renales.

Info

Publication number
MX2024002335A
MX2024002335A MX2024002335A MX2024002335A MX2024002335A MX 2024002335 A MX2024002335 A MX 2024002335A MX 2024002335 A MX2024002335 A MX 2024002335A MX 2024002335 A MX2024002335 A MX 2024002335A MX 2024002335 A MX2024002335 A MX 2024002335A
Authority
MX
Mexico
Prior art keywords
relaxin
vasopressin
administration
compositions
individual
Prior art date
Application number
MX2024002335A
Other languages
English (en)
Spanish (es)
Inventor
Guido Magni
Original Assignee
River 2 Renal Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by River 2 Renal Corp filed Critical River 2 Renal Corp
Publication of MX2024002335A publication Critical patent/MX2024002335A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2024002335A 2021-08-23 2022-08-22 Combinacion de analogos de relaxina y vasopresina para el tratamiento de trastornos y afecciones renales. MX2024002335A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163236090P 2021-08-23 2021-08-23
US202263332994P 2022-04-20 2022-04-20
PCT/US2022/041095 WO2023028008A2 (en) 2021-08-23 2022-08-22 Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions

Publications (1)

Publication Number Publication Date
MX2024002335A true MX2024002335A (es) 2024-05-23

Family

ID=85322130

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024002335A MX2024002335A (es) 2021-08-23 2022-08-22 Combinacion de analogos de relaxina y vasopresina para el tratamiento de trastornos y afecciones renales.

Country Status (7)

Country Link
US (1) US20240400638A1 (https=)
EP (1) EP4392440A4 (https=)
JP (1) JP2024532403A (https=)
AU (1) AU2022334113A1 (https=)
CA (1) CA3229783A1 (https=)
MX (1) MX2024002335A (https=)
WO (1) WO2023028008A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA52994A (fr) * 2018-01-31 2021-05-05 Sanofi Sa Peptides à chaîne b de relaxine lipidés modifiés et leur utilisation thérapeutique
WO2023086913A2 (en) 2021-11-11 2023-05-19 Tectonic Therapeutic, Inc. Relaxin-2 fusion protein analogs and methods of using same
KR20260035823A (ko) 2023-05-18 2026-03-13 테크토닉 오퍼레이팅 컴퍼니 인코포레이티드 렐락신-2 융합 단백질 유사체 및 이를 사용하는 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015528019A (ja) * 2012-07-31 2015-09-24 ノバルティス アーゲー セレラキシンを使用する炎症の処置
CN110637027B (zh) * 2017-02-08 2024-08-30 百时美施贵宝公司 包含药代动力学增强子的修饰的松弛素多肽及其用途
MA52994A (fr) * 2018-01-31 2021-05-05 Sanofi Sa Peptides à chaîne b de relaxine lipidés modifiés et leur utilisation thérapeutique

Also Published As

Publication number Publication date
EP4392440A4 (en) 2025-07-30
AU2022334113A1 (en) 2024-03-14
WO2023028008A2 (en) 2023-03-02
EP4392440A2 (en) 2024-07-03
US20240400638A1 (en) 2024-12-05
WO2023028008A3 (en) 2023-10-26
JP2024532403A (ja) 2024-09-05
CA3229783A1 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
MX2024002335A (es) Combinacion de analogos de relaxina y vasopresina para el tratamiento de trastornos y afecciones renales.
MX2024001205A (es) Combinaciones de agonistas de receptores de hormona tiroidea (tr-\03b2) con compuestos antifibroticos para usarse en tratar enfermedades del higado graso.
AR134152A2 (es) Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
JOP20200137A1 (ar) نظائر إنكريتين واستخداماتها
MX2020009856A (es) Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp).
GT201700056A (es) Uso de agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamento de la enfermedad del hígado graso no alcohólico.
CL2022003733A1 (es) Análogos de nucleósido de 1’-ciano y usos de los mismos
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
CL2020000422A1 (es) Composiciones de glp-1 y sus usos.
MX2020010907A (es) Mejora de suministro de agentes activos lipofilicos a traves de la barrera hematoencefalica y metodos para tratar trastornos del sistema nervioso central.
MX2020002191A (es) Agentes antivirales contra la hepatitis b.
CR20160093A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub aguda o cronica
CL2020003447A1 (es) Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas
SV2017005595A (es) Unidad de dosificacion orodispersable que contiene un componente estetrol
PE20190500A1 (es) Moduladores del receptor nmda spiro-lactam y uso de los mismos
CL2021000030A1 (es) Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales
MX2020007760A (es) Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano.
MX2021002655A (es) Terapia de combinacion para el tratamiento de enfermedad hepatica.
MX2021004566A (es) Compuestos terapeuticos.
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
MX2021005751A (es) Anticuerpos contra mucina 16 y métodos de uso de los mismos.
MX2022001429A (es) Formulaciones que incluyen dihidrohonokiol.
MX2020002156A (es) Composiciones y metodos para el uso anti viral de analogos y mimeticos de lisina sintetica.
CL2017002605A1 (es) Derivados de indol
CL2020002369A1 (es) Preparación farmacéutica o de complemento alimenticio a base de alfa-lactoalbúmina